Frank Mulindwa

Antwerpen, VLG, Belgium

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 20 publications

Effect of weight gain on blood pressure in Ugandan persons with HIV on dolutegravir/lamivudine/ tenofovir disoproxil fumarate over 48 weeks.

Effect of weight gain on blood pressure in Ugandan persons with HIV on dolutegravir/lamivudine/ tenofovir disoproxil fumarate over 48 weeks.

Journal: PloS one
Published: March 19, 2025

Dolutegravir-associated hyperglycemia: a narrative review.

Dolutegravir-associated hyperglycemia: a narrative review.

Journal: AIDS research and therapy
Published: March 13, 2025

Impact of hepatic steatosis on mortality, hepatocellular carcinoma, end-stage liver disease and HBsAg seroclearance in chronic hepatitis B: a United States cohort study.

Impact of hepatic steatosis on mortality, hepatocellular carcinoma, end-stage liver disease and HBsAg seroclearance in chronic hepatitis B: a United States cohort study.

Journal: Frontiers in immunology
Published: January 26, 2025

Chronic Hepatitis B and COVID-19 Clinical Outcomes in the United States: A Multisite Retrospective Cohort Study.

Chronic Hepatitis B and COVID-19 Clinical Outcomes in the United States: A Multisite Retrospective Cohort Study.

Journal: Open forum infectious diseases
Published: August 03, 2024

Self-reported hepatitis B testing among noninstitutionalized adults in the United States before the implementation of universal screening, 2013-2017: A nationwide population-based study.

Self-reported hepatitis B testing among noninstitutionalized adults in the United States before the implementation of universal screening, 2013-2017: A nationwide population-based study.

Journal: Journal of viral hepatitis
Published: January 06, 2024

Association between biomarkers of inflammation and dyslipidemia in drug resistant tuberculosis in Uganda.

Association between biomarkers of inflammation and dyslipidemia in drug resistant tuberculosis in Uganda.

Journal: Lipids in health and disease
Published: December 23, 2023

Should dolutegravir always be withheld in people with HIV on dolutegravir with incident diabetes mellitus? A case report.

Should dolutegravir always be withheld in people with HIV on dolutegravir with incident diabetes mellitus? A case report.

Journal: Research square
Published: September 07, 2023

Blood glucose outcomes of anti-retroviral therapy naïve Ugandan people with HIV with pre-diabetes mellitus initiated on dolutegravir for 48 weeks.

Blood glucose outcomes of anti-retroviral therapy naïve Ugandan people with HIV with pre-diabetes mellitus initiated on dolutegravir for 48 weeks.

Journal: Research square
Published: August 14, 2023

Should dolutegravir always be withheld in people with HIV on dolutegravir with incident diabetes mellitus? a case report.

Should dolutegravir always be withheld in people with HIV on dolutegravir with incident diabetes mellitus? a case report.

Journal: BMC infectious diseases
Published: July 30, 2023

Dolutegravir use over 48 weeks is not associated with worsening insulin resistance and pancreatic beta cell function in a cohort of HIV-infected Ugandan adults.

Dolutegravir use over 48 weeks is not associated with worsening insulin resistance and pancreatic beta cell function in a cohort of HIV-infected Ugandan adults.

Journal: Research square
Published: July 28, 2023

Dolutegravir use over 48 weeks is not associated with worsening insulin resistance and pancreatic beta cell function in a cohort of HIV-infected Ugandan adults.

Dolutegravir use over 48 weeks is not associated with worsening insulin resistance and pancreatic beta cell function in a cohort of HIV-infected Ugandan adults.

Journal: AIDS research and therapy
Published: July 16, 2023

Blood glucose outcomes of anti-retroviral therapy naïve Ugandan people with HIV with pre-diabetes mellitus initiated on dolutegravir for 48 weeks.

Blood glucose outcomes of anti-retroviral therapy naïve Ugandan people with HIV with pre-diabetes mellitus initiated on dolutegravir for 48 weeks.

Journal: BMC infectious diseases
Published: July 10, 2023
Showing 1-12 of 20

Last Updated: 09/26/2026